Janus Henderson Group PLC Trims Stake in Amedisys, Inc. (NASDAQ:AMED)

Janus Henderson Group PLC reduced its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 22.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 285,768 shares of the health services provider’s stock after selling 83,985 shares during the quarter. Janus Henderson Group PLC owned about 0.87% of Amedisys worth $26,340,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its holdings in Amedisys by 0.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,199 shares of the health services provider’s stock worth $2,876,000 after purchasing an additional 255 shares during the period. Alpine Global Management LLC purchased a new position in shares of Amedisys in the 1st quarter valued at $922,000. Covestor Ltd increased its holdings in shares of Amedisys by 134.2% in the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after acquiring an additional 447 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of Amedisys by 5.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 38,403 shares of the health services provider’s stock valued at $3,539,000 after acquiring an additional 1,923 shares during the period. Finally, Swiss National Bank increased its holdings in shares of Amedisys by 5.4% in the 1st quarter. Swiss National Bank now owns 64,400 shares of the health services provider’s stock valued at $5,935,000 after acquiring an additional 3,300 shares during the period. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Stock Up 0.2 %

AMED stock traded up $0.18 on Wednesday, hitting $98.23. 111,123 shares of the company’s stock were exchanged, compared to its average volume of 322,719. Amedisys, Inc. has a 12-month low of $89.55 and a 12-month high of $98.95. The firm has a 50 day moving average price of $94.96 and a two-hundred day moving average price of $93.88. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price on the stock. in a research note on Monday. Finally, StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.